O’Melveny & Myers LLP represented Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) in its proposed public offering. The company, which develops medicines related to cancer treatment, plans to use the proceeds for research and development and general corporate purposes.
The O’Melveny team was led by partners Jennifer DePalma and Sam Zucker, senior counsel Stanton Lovenworth, and counsel Ruchun Ji.
Related Posts:
- O’Melveny Represents Celsion Corporation in a US$15 Million Private Placement
- O’Melveny Represents Alliance Health Networks in Acquisition of Medify
- O’Melveny Represents Cytomx Therapeutics in Expansion of Series B Financing
- O’Melveny Represents Dicerna Pharmaceuticals in US$60 Million Private Financing Transaction
- O’Melveny Represents Celsion in Registered Direct Offering